The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Preoperative Chemoradiation With Capecitabine and Cetuximab
Official Title: Preoperative Chemoradiation With Capecitabine and Cetuximab Within a Multidisciplinary Therapeutic Approach in Patients With Operable T3-T4 Rectal Cancer: a Phase II Study
Study ID: NCT00297128
Brief Summary: * feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma * collection of response rate (T-downstaging, pathological complete remission), correlation of responsiveness with EGFR-status
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hospital BHB St. Veit/Glan, Surgery, St. Veit a. d. Glan, Carinthia, Austria
Hospital Wiener Neustadt, Surgery, Wiener Neustadt, Lower Austria, Austria
Medical University of Graz, Oncology, Graz, Styria, Austria
State Hospital Leoben, Leoben, Styria, Austria
Medical University of Innsbruck, Surgery, Innsbruck, Tyrol, Austria
Hospital BHS Linz, Radiooncology, Linz, Upper Austria, Austria
Klinikum Wels-Grieskirchen, Wels, Upper Austria, Austria
State Hospital Feldkirch, Feldkirch, Vorarlberg, Austria
Paracelsus Medical University Salzburg - Oncology, Salzburg, , Austria
Medical University of Vienna, Radiotherapy, Vienna, , Austria
Name: Josef Thaler, MD
Affiliation: Austrian Breast & Colorectal Cancer Study Group
Role: PRINCIPAL_INVESTIGATOR
Name: Joerg Tschmelitsch, MD
Affiliation: Austrian Breast & Colorectal Cancer Study Group
Role: PRINCIPAL_INVESTIGATOR
Name: Alexander de Vries, MD
Affiliation: Austrian Breast & Colorectal Cancer Study Group
Role: PRINCIPAL_INVESTIGATOR